---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-24-000058"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:44:59.682144+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed

## Summary
- Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.
- Net loss of $22.7M vs $1.3M loss in Q1 2023; Adjusted EBITDA $7.8M vs $23.8M.
- Biologics Safety Testing revenue up 3.4% to $18.2M.
- Reaffirmed FY2024 revenue guidance $265M–$285M.
- Entered non-exclusive CleanCap license agreement with Lonza for mRNA services.

## SEC filing metadata
- accession: 0001823239-24-000058
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/0001823239-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/mrvi-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-24-000058
- JSON: https://secwatch.observer/filing/0001823239-24-000058.json
- Plain text: https://secwatch.observer/filing/0001823239-24-000058.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. updated its first quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: first quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 8, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/0001823239-24-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.